アレイ バイオファーマ社、進行期悪性黒色腫についてbinimetinibおよびencorafenibの新薬承認申請をFDAに提出 ( Array BioPharma Submits New Drug Applications to FDA for Binimetinib and Encorafenib in Advanced Melanoma

By Drugs, Company, Pharmaceutical

アレイ バイオファーマ社、進行期悪性黒色腫についてbinimetinibおよびencorafenibの新薬承認申請をFDAに提出 ニュースリリース｜小野薬品工業株式会社 / 57min ago
http://www.ono.co.jp/jpnw/PDF/n17_0706_2.pdf

Array BioPharma Submits New Drug Applications to FDA for Binimetinib and Encorafenib in Advanced Melanoma News Release / 1 hour ago

http://www.ono.co.jp/eng/news/pdf/sm_cn170706_2.pdf

More from tokioX :

  1. Asthma Drug Alvesco Possibly Effective for COVID-19
  2. Chinese Alzheimer’s drug hits the market
  3. U.S. Government Sues Gilead over Alleged Infringement on HIV Prevention Drug
  4. 💊FDA PHARMA today
  5. 💊European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma
  6. 👾Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy
  7. Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea  20170919